Sichuan Goldstone Asia Pharmaceutical, Inc. Class A

Sichuan Goldstone Asia Pharmaceutical, Inc. Class A

SSZSE:300434
11.15
CNY
-0.51
(-4.37%)
0.43EPS
29.42P/E
5.19BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.3
0.94
0.52
0.67
2.24
2.41
2.51
1.93
2.69
3.07
2.97
2.76
2.6
2.59
Basic EPS, GAAP
0.27
0.17
0.1
0.11
0.37
0.37
0.3
-1.71
0.17
0.54
0.31
0.23
0.33
0.44
Free Cash Flow per Basic Share
0.19
0.03
0.01
-0.25
0.45
0.43
0.4
0.24
0.13
0.66
0.21
0.21
0.27
- -
Dividend per Share
0.05
0.06
0.05
0.03
0.05
0.07
0.09
0.08
- -
- -
- -
0.11
0.07
0.08
Book Value per Share
1.09
1.21
1.57
1.64
6.27
6.58
6.8
5.02
5.19
5.66
5.98
6.09
6.35
6.62
Tangible Book Value per Share
0.99
1.05
1.43
1.5
3.57
3.92
4.23
4.16
4.09
4.61
5.14
5.31
5.62
5.91
Basic Weighted Avg Shares
183
183
224
242
314
403
401
402
391
405
407
399
399
402
Sales/Revenue/Turnover
239
173
117
162
704
971
1,006
777
1,054
1,243
1,209
1,102
1,038
1,040
Operating Margin (%)
22.34
21.07
14.68
12.57
22.34
19.55
18.11
0.76
12.33
23.56
20.5
13.21
15.05
19.43
Depreciation Expense
2
3
3
3
48
81
82
86
87
91
94
105
103
- -
Net Income, GAAP
49
32
23
26
116
149
120
-688
66
219
126
92
132
176
Effective Tax Rate (%)
13.89
12.96
12.85
13.5
22.82
18.81
21.36
- -
29.33
26.67
31.81
27.8
15.81
14.28
Profit Margin (%)
20.5
18.58
19.96
15.72
16.49
15.37
11.97
-88.47
6.31
17.61
10.44
8.32
12.68
16.96
Working Capital
159
164
302
237
314
485
553
563
426
583
770
578
698
668
LT Debt
- -
- -
- -
- -
15
8
- -
- -
1
- -
3
26
- -
2
Total Equity
200
222
384
403
2,554
2,682
2,774
2,059
2,162
2,303
2,424
2,470
2,574
2,681
Return on Invested Capital (%)
25.11
15.05
5.99
5.3
7.54
5.66
4.55
- -
2.94
9.28
4.86
3.66
4.93
6.35
Return on Capital (%)
27
15.24
7.2
6.45
8.17
5.51
4.21
- -
3.16
10.05
5.45
3.77
5.22
6.63
Return on Common Equity (%)
27
15.24
7.73
6.49
7.95
5.78
4.48
-28.96
3.24
10.04
5.4
3.79
5.27
6.86

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
75
106
104
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
402
402
402
Market Capitalization
3,977
4,512
5,191

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,230
1,076
1,118
Cash, Cash Equivalents & STI
337
481
552
Accounts Receivable, Net
101
99
104
Inventories
194
206
208
Total Current Liabilities
424
435
450
Payables & Accruals
- -
- -
- -
ST Debt
75
106
104
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
54.42%
4.58%
4.22%
Free Cash Flow
-214.17%
67.6%
27.1%
Net Income, GAAP
-20.5%
18.65%
43.44%
Sales/Revenue/Turnover
42.71%
7.23%
-5.8%
Total Cash Common Dividend
654.5%
1,270.97%
-36.62%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
363
159
235
346
1,102
2025
291
200
- -
330
1,038
2026
331
159
220
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
-0.13
0.05
0.08
0.23
2025
0.16
0.01
- -
0.09
0.33
2026
0.29
-0.05
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.11
- -
- -
0.11
2025
- -
0.07
- -
- -
0.07
2026
- -
0.08
- -
- -
- -

Company Description

CEO
Yi Ping Ma
Full Time Employees
1,794
Sector
Producer manufacturing
Industry
Miscellaneous manufacturing
Address
No. 4760 Jiangnan Avenue Chengdu HB China 610200
IPO Date
Apr 24, 2015
Business
I did not find relevant information about the latest major company changes for Sichuan Goldstone Asia Pharmaceutical Inc. (Ticker: 300434.SZ) in the initial search. I will perform a focused search specifically for this company using its name and ticker symbol to gather detailed and up-to-date company description data including its main products, services, and recent developments.